Documented mechanisms of action Preclinical studies (mostly Russian, to be reproduced in international protocols) report several mechanistic targets: BDNF increase (Brain-Derived Neurotrophic Factor) in the hippocampus and frontal cortex, measured by ELISA and Western blot 24-72 h post-administration Monoaminergic system modulation : cortical dopamine increase, serotonergic modulation Activation of the melanocortin pathway via MC4R receptors (residue shared with ACTH) Anti-oxidant and anti-apoptotic effect in cerebral ischaemia models (MCAO, middle cerebral artery occlusion) Experimental paradigms The most reported rodent models are the Morris water maze (spatial memory), novel object recognition (recognition memory), passive avoidance (aversive learning)
Cereb Cortex 1:147 Fernndez-Miranda JC, Rhoton AL Jr, Kakizawa Y et al (2008) The claustrum and its projection system in the human brain: a microsurgical and tractographic anatomical study
BPC-157 + TB-500 blends typically contain the two peptides in a ratio ranging from 1:1 to 1:5 in favor of TB-500
Interestingly, a recent clinical report showed that amylin analog pramlintide infusion induced migraine-like attacks in patients similarly to CGRP infusion [40]
Split Dosing Considerations Because BPC-157 has a relatively short half-life of approximately four to six hours, split dosing maintains more consistent tissue levels throughout the day
Laboratory and animal models consistently demonstrate that the pentadecapeptide enhances functional and biomechanical recovery following severe crush injuries, myotendinous tears and systemic tissue degeneration